About Mekonos
Mekonos is a company based in Palo Alto (United States) founded in 2016 by Greg Sitters, Steven Banerjee, and Anil Narasimha. Mekonos has raised $29.6 million across 2 funding rounds from investors including Novartis, Debiopharm and Magnetar Capital. Mekonos operates in a competitive market with competitors including StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
- Headquarter Palo Alto, United States
- Founders Greg Sitters, Steven Banerjee, Anil Narasimha
- SectorsHealthcareTechnology
- Phone•••• ••••
- Website mekonos.com
- Social LinkedIn
- Total Equity Funding$29.6M (USD)
in 2 rounds
- Latest Funding Round$25M (USD), Series A
Nov 2021
- InvestorsNovartis
& 13 more
Funding Insights of Mekonos
Mekonos has successfully raised a total of $29.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.6M
- Total Rounds 2
- Last Round Series A — $25M
- First Round $4.6M
(Nov 2020)
- Investors Count 14
All 2 funding rounds of Mekonos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $25M | Series A | – | Magnetar, TDK Ventures | |
| Nov 2020 | $4.6M | Series A | – | Novartis |
14 investors in total: 14 institutional.
Investors in Mekonos
Mekonos has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Debiopharm and Magnetar Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Magnetar Capital is engaged in alternative asset management. | – | magnetar.com | Evanston, United States | |
Early-stage tech startups are invested in globally by TDK Ventures. | – | tdk-ventures.com | San Jose, United States | |
Investment firm focused on finance and technology opportunities. | – | peak6.com | - | |
Early-stage investments in US Tech and Life Sciences are targeted. | – | drxcapital.com | Basel, Switzerland | |
USA focused VC firm investing in seed and early-stage startups | – | elementum.vc | Menlo Park, United States | |
Investments in multiple sectors are managed by Reimagined Ventures. | – | reimaginedventures.com | Winnetka, United States | |
- | – | fiscusventures.tcc.mode | - | |
Tech startups are funded by S32, a venture capital entity. | – | s32.com | Sunnyvale, United States | |
A venture capital fund focused on artificial intelligence and machine learning is operated. | – | hikevc.com | - | |
Investments are directed toward seed-stage startups by CRCM Ventures. | – | crcmventures.com | San Francisco, United States |
Investor details for Mekonos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mekonos
7 people are tracked at Mekonos (3 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Greg Sitters | Co-Founder | Leadership |
Steven Banerjee | Co-Founder & CEO | Leadership |
Anil Narasimha | Co-Founder & CSO | Leadership |
Charles Nguyen | Systems Integration Engineer | Team |
Marcela Galvis | Sr. Project Manager | Team |
Amir Tahmasebipour | Senior Scientist, Microfluidics | Team |
Jacek Lechowicz | Senior Process Engineer | Team |
Complete people profiles for Mekonos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mekonos
3 dated milestones of Mekonos across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Mekonos is founded.
- Funding First funding round of $4.6M.
- Funding Latest funding round, Series A, of $25.0M.
Competitors of Mekonos
Mekonos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| sixfold.bio | 2017 | London, United Kingdom | $4.59M | 16 | Oligonucleotide delivery systems are developed for targeted gene therapy. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. | |
| vigenebio.com | 2012 | Rockville, United States | $10.5M | 45 | Research reagents for drug discovery and functional genomics are developed. | |
| feldan.com | 2007 | Quebec, Canada | $52.9M | – | Proteins are delivered directly into cells via proprietary shuttle technology. | |
| cellfebiotech.com | 2018 | Berkeley, United States | $26.8M | – | Intracellular gene delivery platform is developed using microfluidic devices. |
Detailed competitors of Mekonos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mekonos
Complete news archive for Mekonos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Mekonos
10 companies that operate in the same segment as Mekonos (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mekonos
Mekonos was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Mekonos is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Steven Banerjee is the current CEO of Mekonos. They have also founded this company.
Mekonos is a funded company, having raised a total of $29.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.6M, raised on Nov 2020.
Mekonos was founded in 2016 and is based in Palo Alto, United States. Nanorobotic chips made from silicon are developed by the company for use in cell engineering. Biomolecules are delivered to cells via these chips to enable genetic modifications. The technology supports cell therapy processes, particularly for cancer treatment, within the biotechnology sector. Operations focus on advancing nanorobotics for therapeutic applications.
Mekonos's top competitors include Phase Genomics, Genedit and CellFE.
Mekonos has 14 investors. Key investors include Novartis, Debiopharm, Magnetar Capital, TDK Ventures, and Sands Capital.